Human Medullary Thyroid Cancer: Xenotransplants and Calcitonin Secretion

1992 ◽  
pp. 144-147
Author(s):  
G. Andry ◽  
P. Lothaire ◽  
P. Vico ◽  
P. Dumont ◽  
D. Larsimont ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Calcitonin Secretion

Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study

2020 ◽  
Author(s):  
Alessandra Dicitore ◽  
Maria Celeste Cantone ◽  
Germano Gaudenzi ◽  
Davide Saronni ◽  
Silvia Carra ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Thyroid Cancer ◽  
Antitumor Activity ◽  
Cell Lines ◽  
Second Generation ◽  
Medullary Thyroid Cancer ◽  
Preclinical Study ◽  
Medullary Thyroid ◽  
Calcitonin Secretion

Introduction: Somatostatin and dopamine receptors have a pivotal role in control of hormone secretion and cell proliferation in different neuroendocrine neoplasms, including medullary thyroid cancer (MTC). In the present preclinical study, we evaluated the antitumor activity of TBR-065 (formerly BIM-23B065), a second-generation somatostatin-dopamine chimera, in two human MTC cell lines. Methods: the effects of lanreotide (LAN) and TBR-065 on the cell growth proliferation, calcitonin secretion, cell cycle, apoptosis, cell migration and tumor-induced angiogenesis have been evaluated through MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, ECLIA assay, wound-healing assay and zebrafish platform, respectively. Results: TBR-065 exerted a more prominent antitumor activity compared to LAN in both MTC cell lines, as shown by inhibition of cell proliferation (maximal inhibition in TT: -50.3% and -37.6%, respectively; in MZ-CRC-1: -58.8% and -27%, respectively) and migration (in TT: -42.7% and -22.9%, respectively; in MZ-CRC-1: -75.5% and -58.2%, respectively). Only the new chimera decreased significantly the fraction of cells in S phase (TT: -33.8%, MZ-CRC-1: -18.8%), and increased cells in G2/M phase (TT: +13%, MZ-CRC-1: +30.5%). In addition, TBR-065 exerted a more prominent pro-apoptotic effect compared to LAN in TT cells. A concomitant decrease of calcitonin secretion was observed after 2 days of incubation with both drugs, with a more relevant effect of TBR-065. However, neither LAN nor TBR-065 showed any effect on tumor-induced angiogenesis, as evaluated using a zebrafish/tumor xenograft model. Discussion/Conclusion: In MTC cell lines a second generation somatostatin-dopamine analogue, TBR-065, exerts a more relevant anti-tumor activity, as compared with LAN, through modulation of cell cycle, induction of apoptosis and reduction in migration. Further studies are required to establish whether TBR-065 has comparable potent inhibitory effects on tumor growth in vivo.

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

2014 ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Malgorzata Kowalska ◽  
Agnieszka Pawlaczek ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Receptor Expression ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation

Clinical usefulness of dynamic risk stratification in medullary thyroid cancer

2016 ◽  
Author(s):  
Ji Min Han ◽  
Hyemi Kwon ◽  
Won Gu Kim ◽  
Min Ji Jeon ◽  
Tae Yong Kim ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Medullary Thyroid Cancer ◽  
Clinical Usefulness ◽  
Medullary Thyroid ◽  
Dynamic Risk

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document